Morus-Gastur Cell Therapeutics Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
- Paid Up Capital ₹ 0.10 M
- Company Age 13 Year, 4 Months
- Last Filing with ROC 31 Mar 2023
- Revenue Growth 48.49%
- Profit Growth -86.34%
- Ebitda -30.81%
- Net Worth 1.06%
- Total Assets 0.36%
About Morus-Gastur Cell Therapeutics
Morus-Gastur Cell Therapeutics Private Limited (MCTPL) is a Private Limited Indian Non-Government Company incorporated in India on 07 September 2011 and has a history of 13 years and four months. Its registered office is in Hyderabad, Telangana, India.
The Corporate was formerly known as Isco Cell Therapeutics Private Limited. The Company is engaged in the Agriculture Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Jayaraman Packirisamy and Kalakata Reddy serve as directors at the Company.
Company Details
-
Location
Hyderabad, Telangana, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
-
Social Media-
Corporate Identity Details
-
CIN/LLPIN
U74120TG2011PTC076359
-
Company No.
076359
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
07 Sep 2011
-
Date of AGM
30 Sep 2023
-
Date of Balance Sheet
31 Mar 2023
-
Listing Status
Unlisted
-
ROC Code
Roc Hyderabad
Industry
Who are the key members and board of directors at Morus-Gastur Cell Therapeutics?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Jayaraman Packirisamy
|
Director | 07-Sep-2011 | Current |
|
Kalakata Reddy
|
Director | 07-Sep-2011 | Current |
Financial Performance of Morus-Gastur Cell Therapeutics.
Morus-Gastur Cell Therapeutics Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 48.49% increase. The company also saw a substantial fall in profitability, with a 86.34% decrease in profit. The company's net worth moved up by a moderate rise of 1.06%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Morus-Gastur Cell Therapeutics?
In 2019, Morus-Gastur Cell Therapeutics had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
-
Sristi Bio-Sciences Private LimitedJayaraman Packirisamy and Kalakata Reddy are mutual person
-
Organova Bio-Agriculture Private LimitedJayaraman Packirisamy is a mutual person
-
Electrospunra Nanofibers (India) Private LimitedJayaraman Packirisamy and Kalakata Reddy are mutual person
-
Insight Bioventures India Private Limited
Jayaraman Packirisamy and Kalakata Reddy are mutual person
-
Qbd Analytics Services Private Limited
Jayaraman Packirisamy and Kalakata Reddy are mutual person
-
Sk Bio Manufacturing Private Limited
Jayaraman Packirisamy is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Morus-Gastur Cell Therapeutics?
Unlock and access historical data on people associated with Morus-Gastur Cell Therapeutics, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Morus-Gastur Cell Therapeutics, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Morus-Gastur Cell Therapeutics's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.